Skip to main
Prescribed Sermorelin

The cited record

Sermorelin References: Every Figure, Carried Back to Its Study

The peer-reviewed and regulatory sources behind every quantitative claim on this site, with DOIs and PubMed links.

Read the researchFollow the mechanism

How to read this list

Each numbered entry below corresponds to the inline markers used across the site. Where a claim reports a dose, a percentage, a duration, or a half-life, it maps to one of these sources. Several adult body-composition and cognition figures derive from the stabilized GHRH analog tesamorelin and are attributed as such in the text; the regulatory and prescribing history is sourced to the editorial and policy record.

  1. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. ↗
  2. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. ↗
  3. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. ↗
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. ↗
  5. Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. ↗
  6. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. (SMART trial, NCT00257712.) ↗
  7. Massoud AF, et al. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin. J Clin Endocrinol Metab. 1991;72(2):492-499. ↗
  8. Lewinski A, et al. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It. Front Endocrinol (Lausanne). 2021;12:636403. ↗
  9. Tauber MT, Pienkowski C, Pigeon P, et al. Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 in children with GH deficiency. Acta Paediatr Suppl. 1993;388:28-30; discussion 31. ↗
  10. Bowers CY, Granda-Ayala R. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine. 2001;14:79-86. ↗
  11. Sáez JM. Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer's disease treatment. Endocr Metab Immune Disord Drug Targets. 2012;12:274-86. ↗
  12. Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. ↗
  13. Cai R, Schally AV, et al. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025. ↗
  14. Schally AV, Cai R, et al. The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders. Rev Endocr Metab Disord. 2025. ↗
  15. Gahete MD, et al. Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond. Rev Endocr Metab Disord. 2025. ↗
  16. Munafo A, Nguyen TX, Papasouliotis O, et al.. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. European journal of endocrinology. 2005. 153:249-56. ↗
  17. Chen RG, Shen YN, Yei J, et al.. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993. 388:32-5; discussion 36. ↗
  18. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism. 1997. 82:1472-9. ↗
  19. Lanes R, Carrillo E. Long-term therapy with a single daily subcutaneous dose of growth hormone releasing hormone (1-29) in prepubertal growth hormone deficient children. Venezuelan Collaborative Study Group. The Journal of pediatric endocrinology. 1994. 7:303-8. ↗
  20. Gelander L, Lindstedt G, Selstam G, et al.. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion. Hormone research. 1989. 31:213-20. ↗
  21. Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. 2026. ↗
  22. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. ↗
  23. Villegas Meza AD, et al.. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS reviews. 2026. 14. ↗
  24. Esposito S, et al.. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. ↗
  25. Prakash A, Goa KL.. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. 12(2):139-157. ↗
  26. Ko FY, Chen WP, Lin CY. Defective response of plasma growth hormone to growth hormone releasing factor in growth hormone deficient children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1992. 33:243-50. ↗
  27. Tuilpakov AN, et al.. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism. 1995. 44:1199-204. ↗
  28. Yuen KC, Biller BM, Molitch ME, Cook DM.. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab. 2009. 94(8):2702-2707. ↗
  29. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Guidance for Industry). FDA Guidance for Industry. 2025. ↗